Biotech big cap Celgene (CELG) grew earnings 20% or more in each of the past nine years. Can the good times continue? Analysts expect EPS to jump 29% this year and 24% in 2016. The number of funds holding shares increased 12% from September to June. The overall stake, though, was flat in the same period. Two highly regarded funds poured in more money.